For this reason and because the majority of approved biosimilars are TNF inhibitors used to treat patients with inflammatory conditions, patients with rheumatoid arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis were more frequently enrolled (38 STPs). Here, TNF is linked to rheumatoid arthritis.